Bevacizumab

Nature Reviews Drug Discovery

Volumn 4, Issue 5 SUPPL., 2005, Pages

  Ellis, Lee M ^a   Kirkpatrick, Peter ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB; ZD 222584; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ADVANCED CANCER; ANGINA PECTORIS; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; META ANALYSIS; METASTASIS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEINURIA; RECTUM CANCER; STROKE; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TUMOR VASCULARIZATION; UNITED STATES; WOUND HEALING IMPAIRMENT; COLORECTAL TUMOR; DRUG ANTAGONISM; REVIEW; TREATMENT OUTCOME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 18744393455     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1727     Document Type: Article

References (13)

1. Ferrara, N. et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug Discov. 3, 391-400 (2004).
2. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
3. Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
4. Presta, L. G. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997).
5. Parkin, D. M. et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4-S66 (2001).
6. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
7. FDA labelling information [online] (2004).
8. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
9. Dias S. et al. Autocrine simulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106, 511-521 (2000).
10. Fan, F. et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24, 2647-2653 (2005).
11. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10, 145-147 (2004).
12. Crane, C. H. et al. Preliminary results of a Phase I study of rhuMab VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP). Proc. ASCO Gastrointestinal Cancers Symp. A85 (2004).
13. Saltz, L. B. et al. Interim report of randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc. ASCO Gastrointestinal Cancers Symp. A169b (2005).